Kuros Biosciences (KURN) CMD 2025 summary

Strategic direction and business transformation

• Transitioned from a hybrid biotech/medtech to a focused medtech company, concentrating on MagnetOs and discontinuing non-core assets.

• Achieved CHF 75.6 million in 2024 sales with 65% year-over-year growth, targeting CHF 220–250 million by 2027.

• Expanded global presence to over 25 countries, with significant growth in the U.S., Europe, and new registrations in New Zealand, UAE, and ongoing processes in Brazil and the Middle East.

• Established dual production footprints in the Netherlands and U.S., digitized supply chain, and implemented ERP for operational efficiency.

• Maintains a profitable, debt-free position, investing operational cash flow into growth, R&D, and selective M&A focused on musculoskeletal applications.

Product innovation and clinical evidence

• MagnetOs, with proprietary NeedleGrip surface technology, demonstrated superior fusion rates to autograft in Level I clinical trials, including 79% vs. 47% overall and 74% vs. 30% in smokers.

• Multiple MagnetOs formulations (Granules, Putty, Easypack Putty, Flex Matrix) address diverse surgical needs and are cleared for spine, extremities, and pelvis.

• Launched MagnetOs MIS for minimally invasive surgery, with further launches and enhancements in the pipeline, including adaptation of surface technology to metals.

• Seven Level I human clinical studies are ongoing, with over 35 studies in total, supporting expansion into new indications such as extremities, trauma, oncology, and osteoporosis.

• MagnetOs contains no human cells or growth factors, minimizing safety concerns and offering broad indications with predictable handling.

Market expansion and commercial strategy

• U.S. is the primary revenue driver (95%), but international sales are targeted to reach 10–15% of total revenue, leveraging distributor models and a scalable sales network (91 to 150 distributors in 2024).

• Entered extremities and trauma markets, with dedicated business units, advisory boards, and tailored sales/marketing resources.

• Strategic alliance with Medtronic accelerates MagnetOs adoption in select spine territories, while Kuros retains all revenue and brand control.

• Pricing strategy leverages clinical evidence to maintain or increase ASP, especially for new, user-friendly product formats.

• Selective M&A approach focuses on high-margin, evidence-based biologics and adjacent technologies, avoiding commodity metals and capital equipment.